BEVERLY HILLS, Calif.

加利福尼亚州比佛利山

,

，

July 16, 2026

2026年7月16日

/PRNewswire/ --

/美通社/ --

Raymond Douglas, MD, PhD

雷蒙德·道格拉斯，医学博士，哲学博士

, a world-renowned thyroid eye disease specialist and oculoplastic surgeon, is the first in the United States to administer LUMVOA ™ (veligrotug-vvze), an infusion therapy for thyroid eye disease (TED), post its FDA-approval. The milestone positions Dr. Douglas and his practice at the center of the next chapter in TED treatment following the FDA approval and launch of Lumvoa by Viridian Therapeutics in late June 2026. .

，一位世界知名的甲状腺眼病专家和眼科整形 surgeon，是美国首位在 LUMVOA™（veligrotug-vvze）获得 FDA 批准后为其患者实施该甲状腺眼病（TED）输液疗法的医生。这一里程碑使 Douglas 博士及其诊所处于甲状腺眼病治疗新篇章的中心位置，紧随 Viridian Therapeutics 于 2026 年 6 月下旬获得 FDA 批准并推出 Lumvoa 之后。

Lumvoa is now the second FDA-approved drug for TED and is indicated for the treatment of thyroid eye disease in both active and chronic disease, giving specialists a newly approved option for a broader TED population. Lumvoa is the first approved TED treatment with labeling that includes data from both active and chronic TED, and it demonstrates statistically significant effects on diplopia response and complete resolution of diplopia in clinical studies..

Lumvoa 现在是第二款获得美国食品药品监督管理局（FDA）批准的用于治疗甲状腺眼病（TED）的药物，适用于活动期和慢性期甲状腺眼病的治疗，为更广泛的甲状腺眼病患者群体提供了新获批的治疗选择。Lumvoa 是首款在说明书中包含活动期和慢性期甲状腺眼病数据的获批治疗药物，并且在临床试验中显示出对复视反应和复视完全缓解具有统计学显著效果。

Thryoid eye disease (TED) is a rare autoimmune condition that can cause proptosis, diplopia, pain, soft tissue inflammation, and, in severe cases, total loss of vision. For ophthalmology and endocrinology audiences, the arrival of another approved targeted therapy is significant because TED treatment has historically relied on corticosteroids, surgery, and limited medical options for patients across different stages of disease. .

甲状腺眼病（TED）是一种罕见的自身免疫性疾病，可导致眼球突出、复视、疼痛、软组织炎症，严重情况下甚至会导致完全失明。对于眼科和内分泌科专业人士而言，另一种获批的靶向疗法的问世意义重大，因为历史上，TED的治疗主要依赖皮质类固醇、手术以及针对不同疾病阶段患者的有限药物治疗选择。

'Lumvoa's approval represents an important advance for physicians treating thyroid eye disease, particularly because it expands the conversation around medical management for both active and chronic TED,' said Raymond Douglas, MD, PhD. 'Being first in the nation to infuse this therapy reflects my practice's commitment to bringing new, evidence-based treatment options to patients as quickly and responsibly as possible.' .

“Lumvoa的获批代表了甲状腺眼病治疗领域的重要进展，尤其因为它拓展了关于活动期和慢性期甲状腺眼病（TED）药物治疗的讨论空间。”Raymond Douglas医学博士、哲学博士表示。“作为全国首家开展该疗法输注治疗的机构，这体现了我们诊所致力于尽快且负责任地为患者提供基于循证医学的新型治疗选择。”

Dr. Douglas has long been associated with innovation in TED care and is widely recognized for his clinical and research leadership in the field. His practice focuses heavily on thyroid eye disease, and his professional profile highlights advanced medical and surgical care for patients with TED. This latest milestone reinforces the private practice's position as a TED Center of Excellence for patients seeking high-acuity TED expertise and access to newly approved therapies. .

道格拉斯博士长期以来与TED（甲状腺眼病）护理领域的创新紧密相连，并因其在该领域的临床和研究领导力而广受认可。他的诊疗工作高度专注于甲状腺眼病，其专业简介突显了为TED患者提供的先进药物和手术治疗。这一最新里程碑进一步巩固了该私立诊所作为“TED卓越中心”的地位，为寻求高难度TED专业诊疗及获得新获批疗法的患者提供服务。

'The opportunity to help shape the field from the first TED biologic, Tepezza (teprotumumab-trbw), to this latest approval is something our entire team is dedicated to,' Dr. Douglas added. 'Being first to infuse Lumvoa is an extension of the work we've done for years to expand treatment options and align therapy with the needs of patients who are living with proptosis, diplopia, and other challenging manifestations of TED.' .

道格拉斯博士补充说：“从首个甲状腺眼病（TED）生物制剂 Tepezza（替普妥单抗-trbw）到此次最新获批，我们有幸参与其中并助力塑造该领域的发展，这是我们整个团队致力于实现的目标。成为首家输注 Lumvoa 的机构，是我们多年来不断拓展治疗选择、使治疗方案与患有眼球突出、复视及其他甲状腺眼病棘手症状的患者需求相契合的工作的延续。”

To ensure that eligible patients can access these therapies, Raymond Douglas MD, PhD pairs clinical expertise with a concierge‑style approach to insurance navigation and care coordination led by Chief Revenue Officer (CRO) and Executive Director of Care Coordination, Karen Mullen. Karen oversees patient‑facing operations and insurance navigation, helping streamline the journey from the initial diagnosis to a patient's last infusion. .

为确保符合条件的患者能够获得这些治疗，Raymond Douglas 医学博士、哲学博士将临床专业知识与由首席营收官（CRO）兼护理协调执行董事 Karen Mullen 领导的管家式保险导航和护理协调服务相结合。Karen 负责监督面向患者的运营和保险导航工作，帮助简化从初次诊断到患者最后一次输注的全过程。

'When a new therapy like Lumvoa becomes available, the clinical decision is only one part of the process; patients also need clarity on coverage, out‑of‑pocket costs, and the steps required for approval,' said Karen Mullen. 'Our team works directly with payers and specialty pharmacies on benefits investigations, prior authorizations, and appeals so that patients with thyroid eye disease are not trying to navigate insurance alone at the same time they're coping with significant visual and quality‑of‑life challenges.' .

“当像Lumvoa这样的新疗法问世时，临床决策只是整个流程的一部分；患者还需要明确保险覆盖范围、自付费用以及获得批准所需的步骤，”Karen Mullen表示。“我们的团队直接与支付方和专科药房合作，进行福利调查、预先授权和申诉工作，以便甲状腺眼病患者在应对严重的视力和生活质量挑战的同时，不必独自面对复杂的保险事务。”

Media Contact

媒体联系人

Morgan Douglas / Marketing Director

摩根·道格拉斯 / 市场总监

248-767-8444 /

248-767-8444 /

[email protected]

[email protected]

About Raymond Douglas, MD, PhD

关于雷蒙德·道格拉斯医学博士、哲学博士

Raymond Douglas, MD, PhD, is an oculoplastic surgeon and thyroid eye disease specialist known for his clinical, academic, and research contributions to the TED field. His practice specializes in cutting-edge medical and surgical care for thyroid eye disease, with a focus on personalized treatment strategies for patients with complex orbital and autoimmune eye conditions.

雷蒙德·道格拉斯（Raymond Douglas），医学博士、哲学博士，是一位眼科整形 surgeon 和甲状腺眼病专家，因其在甲状腺眼病（TED）领域的临床、学术和研究贡献而闻名。他的诊疗实践专注于甲状腺眼病的前沿药物和手术治疗，重点为患有复杂眼眶疾病和自身免疫性眼病的患者提供个体化治疗策略。

Dr. Douglas has been recognized across professional and clinical channels for leadership in TED treatment and innovation. .

道格拉斯博士因在创伤性脑损伤（TED）治疗和创新方面的领导作用，在专业和临床领域广受认可。

SOURCE Dr. Raymond Douglas, MD, PhD

来源：雷蒙德·道格拉斯博士，医学博士，哲学博士

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示